Developing accurate predictive models for patients with pediatric acute myeloid leukemia (AML) can close the preclinical gap in treatment for the rare disease. Unlike adult patients who have patients, ...

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...

(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric ...

Scientists have refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis. Compared to adult cancers, pediatric cancers often have ...

A recent study shows a regimen of low-dose homoharringtonine, cytarabine, and G-CSF (HAG) is an effective and promising treatment for pediatric patients with AML.

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia ...

SELLAS Life Sciences Group, Inc. announced that it has dosed its first pediatric patient in a Phase 2 trial for SLS009 (tambiciclib), a selective CDK9 inhibitor targeting relapsed/refractory acute ...

It seemed as if Logan Jenner had the best possible chance for a cure. Diagnosed at age 3 with acute myeloid leukemia, an aggressive blood cancer, Logan happened to have a targetable mutation that ...

Despite improved outcomes in newly diagnosed pediatric AML, relapsed disease remains a therapeutic challenge. Factors contributing to slow progress in improving outcomes include inherent challenges in ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...